Richard Bartram - 29 Oct 2021 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role: Chief Financial Officer
Signature: /s/ Richard B. Bartram
Issuer symbol: ESPR
Transactions as of: 29 Oct 2021
Net transactions value: $0
Form type: 4
Filing time: 01 Nov 2021, 16:48:31 UTC
Previous filing: 30 Jun 2021
Next filing: 16 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ESPR	Common Stock	Award	$0	+18,700	+74%	$0.000000	43,852	29 Oct 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ESPR	Stock Option (right to buy)						26,500	29 Oct 2021	Common Stock	26,500	$8.94	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The awards will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label.
F2	Consists of 43,852 shares of common stock held, including 1,535 shares acquired in Esperion's Employee Stock Purchase Plan.